Lack of absent in melanoma 2 (AIM2) expression in tumor cells is closely associated with poor survival in colorectal cancer patients

International Journal of Cancer

Volumn 135, Issue 10, 2014, Pages 2387-2396

  Dihlmann, Susanne ^a   Tao, Sha ^b   Echterdiek, Fabian ^a,b,c   Herpel, Esther ^a,b   Jansen, Lina ^b   Chang Claude, Jenny ^b   Brenner, Hermann ^b   Hoffmeister, Michael ^b   Kloor, Matthias ^a,b,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

Cancer prognosis; Inflammation; Interferon (IFN); Tissue microarray; Tumor marker

Indexed keywords

AIM2 GENE; ARTICLE; CANCER CELL; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE MARKER; EPITHELIUM CELL; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; ADENOCARCINOMA; AGED; CASE CONTROL STUDY; COHORT ANALYSIS; COLON; COLORECTAL TUMOR; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; INFLAMMATION; INTERFERON (IFN); LYMPH NODE METASTASIS; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RECTUM; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

AIM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; TUMOR MARKER;

CANCER PROGNOSIS; INFLAMMATION; INTERFERON (IFN); TISSUE MICROARRAY; TUMOR MARKER;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; COLON; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; RECTUM; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84909945799     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28891     Document Type: Article

References (36)

1. Sobin LH, Wittekind C, eds. TNM classification of malignant tumours, 7th ed. New York, Chichester, Weinheim, Brisbane, Singapore, Toronto: Wiley Blackwell, 2009.
2. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008;134:1296-310.
3. Petersen SH, Harling H, Kirkeby LT, et al. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012;3:CD004078.
4. Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370:2020-9.
5. Wu X, Zhang J, He X, et al. Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. J Gastrointest Surg 2012;16:646-55.
6. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2013 [Epub ahead of print].
7. Bilchik A, Nissan A, Wainberg Z, et al. Surgical quality and nodal ultrastaging is associated with long-term disease-free survival in early colorectal cancer: an analysis of 2 international multicenter prospective trials. Ann Surg 2010;252:467-74; discussion 74-6.
8. Bacolod MD, Barany F. Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann Surg Oncol 2011;18:3694-700.
9. Schulmann K, Brasch FE, Kunstmann E, et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology 2005;128:590-9.
10. Woerner SM, Kloor M, Mueller A, et al. Microsatellite instability of selective target genes in HNPCC-associated colon adenomas. Oncogene 2005;24:2525-35.
11. Woerner SM, Kloor M, Schwitalle Y, et al. The putative tumor suppressor AIM2 is frequently affected by different genetic alterations in microsatellite unstable colon cancers. Genes Chromosomes Cancer 2007;46:1080-9.
12. Michel S, Kloor M, Singh S, et al. Coding microsatellite instability analysis in microsatellite unstable small intestinal adenocarcinomas identifies MARCKS as a common target of inactivation. Mol Carcinog 2010;49:175-82.
13. Patsos G, Germann A, Gebert J, et al. Restoration of absent in melanoma 2 (AIM2) induces G2/M cell cycle arrest and promotes invasion of colorectal cancer cells. Int J Cancer 2010;126:1838-49.
14. Lee J, Li L, Gretz N, et al. Absent in Melanoma 2 (AIM2) is an important mediator of interferon-dependent and -independent HLA-DRA and HLA-DRB gene expression in colorectal cancers. Oncogene 2012;31:1242-53.
15. Alnemri ES. Sensing cytoplasmic danger signals by the inflammasome. J Clin Immunol 2010;30:512-9.
16. Brenner H, Chang-Claude J, Seiler CM, et al. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 2011;154:22-30.
17. Kahlert C, Gaitzsch E, Steinert G, et al. Expression analysis of aldehyde dehydrogenase 1A1 (ALDH1A1) in colon and rectal cancer in association with prognosis and response to chemotherapy. Ann Surg Oncol 2012;19:4193-201.
18. Rudolph A, Toth C, Hoffmeister M, et al. Expression of oestrogen receptor beta and prognosis of colorectal cancer. Br J Cancer 2012;107:831-9.
19. Hakimi M, Peters A, Becker A, et al. Inflammation-related induction of absent in melanoma 2 (AIM2) in vascular cells and atherosclerotic lesions suggests a role in vascular pathogenesis. J Vasc Surg 2014;59:794-803e2.
20. Zhang X, Loberiza FR, Klein JP, et al. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed 2007;88:95-101.
21. DeYoung KL, Ray ME, Su YA, et al. Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene 1997;15:453-57.
22. Chen IF, Ou-Yang F, Hung JY, et al. AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. Mol Cancer Ther 2006;5:1-7.
23. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002;13:95-109.
24. Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 2005;307:1904-09.
25. Fernandes-Alnemri T, Yu JW, Datta P, et al. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009;458:509-13.
26. Hornung V, Ablasser A, Charrel-Dennis M, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009;458:514-8.
27. Roberts TL, Idris A, Dunn JA, et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 2009;323:1057-60.
28. Burckstummer T, Baumann C, Bluml S, et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009;10:266-72.
29. Dombrowski Y, Peric M, Koglin S, et al. Cytosolic DNA triggers inflammasome activation inkeratinocytes in psoriatic lesions. Sci Transl Med 2011;3:82ra38.
30. Kopfnagel V, Wittmann M, Werfel T. Human keratinocytes express AIM2 and respond to dsDNA with IL-1beta secretion. Exp Dermatol 2011;20:1027-9.
31. de Koning HD, Bergboer JG, van den Bogaard EH, et al. Strong induction of AIM2 expression in human epidermis in acute and chronic inflammatory skin conditions. Exp Dermatol 2012;21:961-4.
32. Reinholz M, Kawakami Y, Salzer S, et al. HPV16 activates the AIM2 inflammasome in keratinocytes. Arch Dermatol Res 2013.
33. Hakimi M, Peters A, Becker A, et al. Inflammation-related induction of absent in melanoma 2 (AIM2) in vascular cells and atherosclerotic lesions suggests a role in vascular pathogenesis. J Vasc Surg 2014;59:794-803.
34. Ponomareva L, Liu H, Duan X, et al. AIM2, an interferon-inducible cytosolic DNA sensor, in the development of benign prostate hyperplasia and prostate cancer. Mol Cancer Res 2013;11:1193-202.
35. Church D, Midgley R, Kerr D. Biomarkers in early-stage colorectal cancer: ready for prime time? Dig Dis 2012;30(Suppl 2):27-33.
36. Chung C, Christianson M. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. J Oncol Pharm Pract 2013;20:11-28.